On Monday, Immuneering Corp (NASDAQ: IMRX) was -8.27% drop from the session before settling in for the closing price of $1.33. A 52-week range for IMRX has been $1.05 – $10.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -43.59%. When this article was written, the company’s average yearly earnings per share was at -6.00%. With a float of $21.00 million, this company’s outstanding shares have now reached $29.27 million.
The extent of productivity of a business whose workforce counts for 68 workers is very important to gauge.
Immuneering Corp (IMRX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Immuneering Corp stocks. The insider ownership of Immuneering Corp is 29.16%, while institutional ownership is 34.33%. The most recent insider transaction that took place on Apr 01 ’24, was worth 1,160,181. In this transaction 10% Owner of this company sold 400,000 shares at a rate of $2.90, taking the stock ownership to the 2,895,273 shares. Before that another transaction happened on Mar 22 ’24, when Company’s Director bought 25,000 for $2.55, making the entire transaction worth $63,713. This insider now owns 111,766 shares in total.
Immuneering Corp (IMRX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -6.00% per share during the next fiscal year.
Immuneering Corp (NASDAQ: IMRX) Trading Performance Indicators
You can see what Immuneering Corp (IMRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 14.38.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.86, a number that is poised to hit -0.52 in the next quarter and is forecasted to reach -1.72 in one year’s time.
Technical Analysis of Immuneering Corp (IMRX)
The latest stats from [Immuneering Corp, IMRX] show that its last 5-days average volume of 15.65 million was superior to 0.94 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 29.20%. Additionally, its Average True Range was 0.17.
During the past 100 days, Immuneering Corp’s (IMRX) raw stochastic average was set at 3.43%, which indicates a significant decrease from 17.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 115.01% in the past 14 days, which was lower than the 165.97% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3215, while its 200-day Moving Average is $4.0667. Now, the first resistance to watch is $1.3467. This is followed by the second major resistance level at $1.4733. The third major resistance level sits at $1.5967. If the price goes on to break the first support level at $1.0967, it is likely to go to the next support level at $0.9733. Assuming the price breaks the second support level, the third support level stands at $0.8467.
Immuneering Corp (NASDAQ: IMRX) Key Stats
There are 29,653K outstanding shares of the company, which has a market capitalization of 36.17 million. As of now, sales total 0 K while income totals -53,470 K. Its latest quarter income was 0 K while its last quarter net income were -14,310 K.
